Cancer Screening Market in the U.K. (2018-2023)
The report is sent in 5-10 business days after order is placed.
Cancer screening market in the U.K.
The United Kingdom (U.K.) stands next to the United States of America (U.S.A.) in coming up with latest technologies to combat the spread of cancer. The cancer screening market in the U.K. is expected to reach USD Bn by 2023 at a CAGR of 8.5%.
Cancer screening market in the U.K. is classified by end users, screening type, and applications. By end users, it is further classified into hospitals, laboratories and independent physicians and clinics. By screening type, it is classified into laboratory, genetic, biopsy, imaging and endoscopy testing. By application type, it is further classified into lung, breast, melanoma, kidney and colorectal type.
Key growth factors
Increasing prevalence of cancer, funded initiatives from the government side and the growing trend to follow a sedentary lifestyle are the key growth factors in this region.
Threats and key players
The complicated regulatory framework has the potential to halt the growth of the market. The exorbitant cost of the services and medicinal methodologies can cease he growth of the market.
The key players operating in the valve market are Abbott Healthcare, Agilent, Becton Dickinson, Biomedical Diagnostics, Qiagen, Thermo Fisher Scientific and Bio-Rad.
What is covered in the report?
1. Overview of the cancer screening market in the U.K.
2. Market drivers and challenges in the cancer screening market in the U.K.
3. Market trends in the cancer screening market in the U.K.
4. Historical, current and forecasted market size data for segments based on end users (hospitals, laboratories and independent physicians and clinics).
5. Historical, current and forecasted market size data for segments based on screening type (laboratory, genetic, biopsy, imaging and endoscopy testing).
6. Historical, current and forecasted market size data for segmentation based on application type (lung, breast, melanoma, kidney and colorectal cancer).
7. Analysis of the competitive landscape and profiles of the major companies operating in the market.
Why buy?
With the given market data, Netscribes offers customizations according to specific needs.
Cancer screening market in the U.K.
The United Kingdom (U.K.) stands next to the United States of America (U.S.A.) in coming up with latest technologies to combat the spread of cancer. The cancer screening market in the U.K. is expected to reach USD Bn by 2023 at a CAGR of 8.5%.
Cancer screening market in the U.K. is classified by end users, screening type, and applications. By end users, it is further classified into hospitals, laboratories and independent physicians and clinics. By screening type, it is classified into laboratory, genetic, biopsy, imaging and endoscopy testing. By application type, it is further classified into lung, breast, melanoma, kidney and colorectal type.
Key growth factors
Increasing prevalence of cancer, funded initiatives from the government side and the growing trend to follow a sedentary lifestyle are the key growth factors in this region.
Threats and key players
The complicated regulatory framework has the potential to halt the growth of the market. The exorbitant cost of the services and medicinal methodologies can cease he growth of the market.
The key players operating in the valve market are Abbott Healthcare, Agilent, Becton Dickinson, Biomedical Diagnostics, Qiagen, Thermo Fisher Scientific and Bio-Rad.
What is covered in the report?
1. Overview of the cancer screening market in the U.K.
2. Market drivers and challenges in the cancer screening market in the U.K.
3. Market trends in the cancer screening market in the U.K.
4. Historical, current and forecasted market size data for segments based on end users (hospitals, laboratories and independent physicians and clinics).
5. Historical, current and forecasted market size data for segments based on screening type (laboratory, genetic, biopsy, imaging and endoscopy testing).
6. Historical, current and forecasted market size data for segmentation based on application type (lung, breast, melanoma, kidney and colorectal cancer).
7. Analysis of the competitive landscape and profiles of the major companies operating in the market.
Why buy?
- Understand the demand for cancer screening market in the U.K. to determine the viability of the market.
- Identify the developed and emerging markets where cancer screening market in the U.K. are sold.
- Identify the challenge areas and address them.
- Develop strategies based on the drivers, trends and highlights for each of the segments.
- Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
- Recognize the key competitors of this market and respond accordingly.
- Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.
- Define the competitive positioning by comparing the products and services with the key players in the market.
With the given market data, Netscribes offers customizations according to specific needs.
CHAPTER 1: EXECUTIVE SUMMARY
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary
CHAPTER 2: CANCER SCREENING MARKET IN THE U.K. MARKET OVERVIEW
2.1. The U.K. market overview market trends, market attractiveness analysis, geography-wise market revenue (USD)
2.2. The U.K. market drivers and challenges
2.3. Value chain analysis cancer screening market in the U.K.
2.4. Porter’s five forces analysis
CHAPTER 3. CANCER SCREENING MARKET IN THE U.K. BY END USERS
3.1. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. Laboratories Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. Independent physicians and clinics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
CHAPTER 4. CANCER SCREENING MARKET IN THE U.K. BY SCREENING TYPE
4.1. Laboratory testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. Genetic testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. Imaging testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. Biopsy testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.5. Endoscopy testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
CHAPTER 5. CANCER SCREENING MARKET IN THE U.K. BY APPLICATION
5.1. Lung cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. Breast cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. Melanoma cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. Kidney cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.5. Colorectal cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
CHAPTER 6: COMPETITIVE LANDSCAPE
6.1. Abbott Laboratories (*)
6.1. a. Company snapshot
6.1. b. Product offerings
6.1. c. Growth strategies
6.1. d. Initiatives
6.1. e. Geographical presence
6.1. f. Key numbers
6.2. Agilent Technologies
6.3. Becton Dickinson
6.4. Biomedical Diagnostics
6.5. Qiagen
6.6. Thermo Fisher Scientific
6.7. Bio-Rad
(*) all the information are similar for the mentioned companies
CHAPTER 7: CONCLUSION
CHAPTER 8: APPENDIX
8.1. List of tables
8.2. Assumptions
8.3. Research and methodology
8.4. About Netscribes Inc.
Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research. Disclaimer: The report will be delivered within 5-7 business days post payment confirmation
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary
CHAPTER 2: CANCER SCREENING MARKET IN THE U.K. MARKET OVERVIEW
2.1. The U.K. market overview market trends, market attractiveness analysis, geography-wise market revenue (USD)
2.2. The U.K. market drivers and challenges
2.3. Value chain analysis cancer screening market in the U.K.
2.4. Porter’s five forces analysis
CHAPTER 3. CANCER SCREENING MARKET IN THE U.K. BY END USERS
3.1. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. Laboratories Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. Independent physicians and clinics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
CHAPTER 4. CANCER SCREENING MARKET IN THE U.K. BY SCREENING TYPE
4.1. Laboratory testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. Genetic testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. Imaging testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. Biopsy testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.5. Endoscopy testing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
CHAPTER 5. CANCER SCREENING MARKET IN THE U.K. BY APPLICATION
5.1. Lung cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. Breast cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. Melanoma cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. Kidney cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.5. Colorectal cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
CHAPTER 6: COMPETITIVE LANDSCAPE
6.1. Abbott Laboratories (*)
6.1. a. Company snapshot
6.1. b. Product offerings
6.1. c. Growth strategies
6.1. d. Initiatives
6.1. e. Geographical presence
6.1. f. Key numbers
6.2. Agilent Technologies
6.3. Becton Dickinson
6.4. Biomedical Diagnostics
6.5. Qiagen
6.6. Thermo Fisher Scientific
6.7. Bio-Rad
(*) all the information are similar for the mentioned companies
CHAPTER 7: CONCLUSION
CHAPTER 8: APPENDIX
8.1. List of tables
8.2. Assumptions
8.3. Research and methodology
8.4. About Netscribes Inc.
Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research. Disclaimer: The report will be delivered within 5-7 business days post payment confirmation
